MicroRNA 1827 (miR-1827)

MicroRNA 1827 (miR-1827) is a short (approximately 20-24 nucleotides) non-coding RNA molecule that controls gene expression post-transcriptionally by either inhibiting mRNA translation or promoting mRNA decay. miR-1827 is synthesized as part of a primary transcript, processed via the Drosha and Dicer enzymes, and incorporated into the RNA-induced silencing complex (RISC). Emerging evidence identifies miR-1827 as a tumor suppressor, particularly in lung adenocarcinoma, where it represses cell migration, invasion, and angiogenesis, mainly by targeting oncogenic mRNAs such as MYC, FAM83F, and CRKL. Expression levels of miR-1827 are associated with tumor progression, making it a candidate biomarker and possible target for molecular therapy in cancer. Its broad regulatory roles and delivery concerns are important considerations for therapeutic development.

Other names

MIR1827hsa-mir-1827MIRN1827

miR-1827 mimics downregulate oncogenic targets (MYC, FAM83F, CRKL) by binding to the 3'-UTRs of their mRNAs, inhibiting translation and reducing cancer progression. Inhibitors of miR-1827 may reverse its tumor-suppressive effects.